

EXHIBIT D-4

Table D-4

Original Group V Claims	'422 Pharmaceutical Composition Claims
<p>55. A pharmaceutical composition comprising an effective amount of a polypeptide according to claims 1, 16, 39, 40, or 41 and a pharmaceutically acceptable diluent, adjuvant, or carrier.</p> <p>56. A method for providing erythropoietin therapy to a mammal comprising administering an effective amount of a polypeptide according to claims 1, 16, 39, 40, or 41.</p> <p>57. A method according to claim 56 wherein the therapy comprises enhancing hematocrit levels.</p>	<p>1. A pharmaceutical composition comprising a therapeutically effective amount of human erythropoietin and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein said erythropoietin is purified from mammalian cells grown in culture.</p> <p>2. A pharmaceutically-acceptable preparation containing a therapeutically effective amount of erythropoietin wherein human serum albumin is mixed with said erythropoietin.</p>